Archive for the ‘ Rehabilitation ’ Category

Cannabigerol aka CBG (not THC or CBD…)

Cannabigerol helps grow new brain cells.  It’s a no-brainer (heh) to use it in cases of head injuries or disorders??!

Ask anyone related to head injuries why they were never told to use this element.  They will not get a serious answer from the doctor who prescribes the contrary medications being pushed by the empire of LEGAL drugs in America.

Dr Sanja Gupta

Can and will this misery ever end?  THEY HAVE BEEN IGNORANT TO THE FACTS FOR OVER VARIOUS DECADES!!!

Many are counting on that CHANGE… Mr. President… Even Dr. Sunja Gupta has given into nature, all your bases belong to us… (the people)… AYBBTU

The Whole World is Watching.  Join us on http://www.Facebook.com/MarihuanaNews !

Legalize Cannabis Nationwide along with Hemp stalks while the bigots are tied up with their internal wars.  No sense in dragging out others wars that bring no benefit.  If human casualty surpasses the benefits… then it is UN-NECESSARY.

Planta Med. 1987 Jun;53(3):277-80.

Identification of a new chemotype in Cannabis sativa: cannabigerol-dominant plants, biogenetic and agronomic prospects.

PMID:  3628560

 [PubMed – indexed for MEDLINE]

LinkOut – more resources

Full Text Sources

1Enough is Enough!  Join us at The American Activist Project on facebook here:

Facebook.com/groups/TAMAP (We have a chat room too. )

Washington Liquor Control Board to Invent a Pot Market, From Seed to Store

The state Liquor Control Board has an interesting job in the year ahead: to get into the weeds of how marijuana is grown, sold and used.
By The Seattle Times – Monday, December 3 2012

 

Washington voters’ decision to legalize marijuana means the state Liquor Control Board (LCB) now has a year to set regulations for the first-of-its-kind marijuana market.

But first, the small state agency must go on an even stranger mission — to get into the, well, weeds of how marijuana is grown, sold and used.  I hope that the people give them hell for NOW trying to profit from it all lol.

At a hearing on Friday before a state Senate committee, Pat Kohler, the LCB director, said the agency would need to hire a consultant — a pot expert — to gather input from key groups of police, farmers, users and others to help her staff better “understand the product and the industry itself.”

The agency has been getting a lot of advice, said Rick Garza, Kohler’s deputy. “There’s a lot of people who think they have a lot of experience in this area,” Garza said, prompting laughs from lawmakers.

The voter-approved Initiative 502 requires the LCB to license and regulate a seed-to-store closed marijuana market, with the first licenses to be issued in late 2013. Based on a state fiscal analysis, it will be a big market: 363,000 users consuming 187,000 pounds of marijuana each year, with steep sin taxes generating more than $560 million a year.

– Article from The Seattle Times.

Marijuana legalization measure requires 40 staffers and a pot expert
Jonathan Martin, Seattle Times

The Washington State Liquor Control Board says it needs to hire 40 additional staff and bring an outside expert in marijuana to implement the voter-approved marijuana legalization measure.

In a briefing to a Senate committee in Olympia on Friday, LCB director Pat Kohler said the biggest challenge of setting up a regulated marijuana market was “understanding the product and the industry itself.”

“There’s a lot of people who think they have a lot of experience in this area,” joked Rick Garza, Kohler’s deputy.

The LCB is taking the lead in creating rules for state-licensed marijuana stores, growers and processors called for in Initiative 502, which passed 56-44 on Nov. 6. Friday’s hearing was the first chance for lawmakers to ask questions about the historic measure.

Kohler estimated there could be 328 stores – the same number of liquor stores under the now-defunct state liquor monopoly – but her staff needed to better understand potential customer demand, among other things. A state fiscal analysis predicted that 363,000 state residents would buy from the state stores, based on federal use surveys.

I really hope they dont try to set up some stereotypical stoner kid to be the “expert”. It SHOULD be a middle aged, regular consumer, who has struggled with other health problems or even addictions and overcome them. Someone who has done hours upon hours of research and study into the effects of medicinal uses, habitual use, as well as occasional “social” use. My fear is that they will appoint a bunch of cops to regulate it, and politicians to commercialize it.
They should be professional, knowledgeable, and intelligent.

P.S.
Im perfect for this job!!!!

The Top Five Special Interest Groups Lobbying To Keep Marijuana Illegal

Google ChromeScreenSnapz018
POSTED BY 

Last year, over 850,000 people in America were arrested for marijuana-related crimes. Despite public opinion, the medical community, and human rights experts all moving in favor of relaxing marijuana prohibition laws, little has changed in terms of policy.

There have been many great books and articles detailing the history of the drug war. Part of America’s fixation with keeping the leafy green plant illegal is rooted in cultural and political clashes from the past.

However, we at Republic Report think it’s worth showing that there are entrenched interest groups that are spending large sums of money to keep our broken drug laws on the books:

1.) Police Unions: Police departments across the country have become dependent on federal drug war grants to finance their budget. In March, we published a story revealing that a police union lobbyist in California coordinated the effort to defeat Prop 19, a ballot measure in 2010 to legalize marijuana, while helping his police department clients collect tens of millions in federal marijuana-eradication grants. And it’s not just in California. Federal lobbying disclosures show that other police union lobbyists have pushed for stiffer penalties for marijuana-related crimes nationwide.

2.) Private Prisons Corporations: Private prison corporations make millions by incarcerating people who have been imprisoned for drug crimes, including marijuana. As Republic Report’s Matt Stoller noted last year, Corrections Corporation of America, one of the largest for-profit prison companies, revealed in a regulatory filing that continuing the drug war is part in parcel to their business strategy. Prison companies have spent millions bankrolling pro-drug war politicians and have used secretive front groups, like the American Legislative Exchange Council, to pass harsh sentencing requirements for drug crimes.

3.) Alcohol and Beer Companies: Fearing competition for the dollars Americans spend on leisure, alcohol and tobacco interests have lobbied to keep marijuana out of reach. For instance, the California Beer & Beverage Distributors contributed campaign contributions to a committee set up to prevent marijuana from being legalized and taxed.

4.) Pharmaceutical Corporations: Like the sin industries listed above, pharmaceutical interests would like to keep marijuana illegal so American don’t have the option of cheap medical alternatives to their products. Howard Wooldridge, a retired police officer who now lobbies the government to relax marijuana prohibition laws, told Republic Report that next to police unions, the “second biggest opponent on Capitol Hill is big PhRMA” because marijuana can replace “everything from Advil to Vicodin and other expensive pills.”

5.) Prison Guard Unions: Prison guard unions have a vested interest in keeping people behind bars just like for-profit prison companies. In 2008, the California Correctional Peace Officers Association spent a whopping $1 million to defeat a measure that would have “reduced sentences and parole times for nonviolent drug offenders while emphasizing drug treatment over prison.” Continue reading

Toxicological Adverse Effects

Common Terminology Criteria for Adverse Events (CTCAE) and more

ctep.cancer.gov/reporting/ctc.html

Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC).

  • A key element of the reorientation of toxicity testing is the way in which adverse effects are understood, the topic of this post. Currently, the adverse effects “credible publications” are manipulated by the gov .. why?!??   Answer: corruption/profit.  This should cease and desist, humans should not be hurt & abused for profits in a republic where democracy thrives and justice prevails.

What is Toxicology?

www.toxicologysource.com/whatistoxicology.html

Toxicology is the study of the adverse effects of chemicals on living systems, whether they be human, animal, plant or microbe.

PUFMM | People United For Medicinal Marijuana

The government sayes its a schedule I , that is to say it has no medical use . But the synthetic form of THC, the main chemical ingredient in the cannabis plant is curently classified as schedule III, a prescribed pill trademarked as marinol.

Medical Marijuana has now been decriminalized in 16 U.S. states & in Cannada.

The American Medical Association & American College of Physicians have both called on the federal government to review cannabis as a schdule I substance.

The National Cancer Institute, a part of the National Institute of health, added cannabis to its website last year as a Complementary Alternative Medicine (CAM), & recoginzed that,”Cannabis has been used for medicinal purposes for thousands of years prior to its current status as an illegal substance.” It also has a 80% approval rating among Americans according to several polls.

EDUCATION IS TRUTH,. GET EDUCATED ,. GET IT DECRIMINALIZED,!!!!

Our #PUFMM Links

ENJOY!

 

 

Medical marijuana monopoly

Currently, the National Institute on Drug Abuse (NIDA) has a monopoly on the supply of research-grade marijuana, but no other Schedule I drug, that can be used in FDA-approved research. NIDA uses its monopoly power to obstruct research that conflicts with its vested interests. MAPS had two of its FDA-approved medical marijuana protocols rejected by NIDA, preventing the studies from taking place. MAPS has also been trying without success for almost four years to purchase 10 grams of marijuana from NIDA for research into the constituents of the vapor from marijuana vaporizers, a non-smoking drug delivery method that has already been used in one FDA-approved human study.

NIDA has a government granted monopoly on the production of medical marijuana for research purposes. In the past, the institute has refused to supply marijuana to researchers who had obtained all other necessary federal permits. Medical marijuana researchers and activists claim that NIDA, which is not supposed to be a regulatory organization, does not have the authority to effectively regulate who does and doesn’t get to do research with medical marijuana. Jag Davies of the Multidisciplinary Association for Psychedelic Studies (MAPS) writes in MAPS Bulletin:[27]

NIDA administers a contract with the University of Mississippi to grow the nation’s only legal cannabis crop for medical and research purposes,[28] including the Compassionate Investigational New Drug program. A Fast Company magazine article pointed out, “Based on the photographic evidence, NIDA’s concoction of seeds, stems, and leaves more closely resembles dried cat brier than cannabis”.[29] An article in Mother Jones magazine describes their crop as “brown, stems-and-seeds-laden, low-potency pot—what’s known on the streets as “schwag””aka “Bobby Brown”[30] United States federal law currently registers cannabis as a Schedule I drug. Medical marijuana researchers typically prefer to use high-potency marijuana, but NIDA’s National Advisory Council on Drug Abuse has been reluctant to provide cannabis with high THC levels, citing safety concerns:[28]

Most clinical studies have been conducted using cannabis cigarettes with a potency of 2-4% THC. However, it is anticipated that there will be requests for cannabis cigarettes with a higher potency or with other mixes of cannabinoids. For example, NIDA has received a request for cigarettes with an 8% potency. The subcommittee notes that very little is known about the clinical pharmacology of this higher potency. Thus, while NIDA research has provided a large body of literature related to the clinical pharmacology of cannabis, research is still needed to establish the safety of new dosage forms and new formulations.

Speaking before the National Advisory Council on Drug Abuse, Rob Kampia of the Marijuana Policy Project criticized NIDA for refusing to provide researcher Donald Abrams with marijuana for his studies, stating that “after nine months of delay, Dr. Leshner rejected Dr. Abrams’ request for marijuana, on what we believe are political grounds that the FDA-approved protocol is inadequate.”[31]

In May 2006, the Boston Globe reported that:[32]

Then again, it’s not in NIDA’s job description-or even, perhaps, in NIDA’s interests-to grow a world-class marijuana crop. The institute’s director, Nora Volkow, has stressed that it’s “not NIDA’s mission to study the medicinal use of marijuana or to advocate for the establishment of facilities to support this research.” Since NIDA’s stated mission “is to lead the Nation in bringing the power of science to bear on drug abuse and addiction,” federally supported marijuana research will logically tilt toward the potential harms, not benefits, of cannabis.

Ricaurte’s monkeys

For more details on this topic, see Retracted article on neurotoxicity of ecstasy.

NIDA has drawn criticism for continuing to provide funding to George Ricaurte, who in 2002 conducted a study that was widely touted as proving that MDMA causeddopaminergic neurotoxicity in monkeys.[33] His paper “Severe Dopaminergic Neurotoxicity in Primates After a Common Recreational Dose Regimen of MDMA (‘Ecstasy’)” inScience[34] was later retracted after it became clear that the monkeys had in fact been injected not with MDMA, but with extremely high doses of methamphetamine.[35] A FOIArequest was subsequently filed by MAPS to find out more about the research and NIDA’s involvement in it.[36][37]

Alan Leshner, publisher of Science and former director of the National Institute on Drug Abuse (NIDA), has come under fire for endorsing the botched study at its time of publication… Leshner did help NIDA bring home the bacon: NIDA’s budget for Ecstasy research has more than quadrupled over the past five years, from $3.4 million to $15.8 million; the agency funds 85 percent of the world’s drug-abuse research. In 2001, Leshner testified before a Senate subcommittee on “Ecstasy Abuse and Control”; critics say Leshner manipulated brain scans from a 2000 study by Dr. Linda Chang showing no difference between Ecstasy users and control subjects. But NIDA insists it’s independent from political pressures. “We don’t set policy; we don’t create laws,” says Beverly Jackson, the agency’s spokesperson.

Effectiveness of anti-marijuana ad campaigns

In February 2005, Westat, a research company hired by NIDA and funded by The White House Office of National Drug Control Policy, reported on its five-year study of the government ad campaigns aimed at dissuading teens from using marijuana, campaigns that cost more than $1 billion between 1998 and 2004. The study found that the ads did not work: “greater exposure to the campaign was associated with weaker anti-drug norms and increases in the perceptions that others use marijuana.” NIDA leaders and the White House drug office did not release the Westat report for a year and a half. NIDA dated Westat’s report as “delivered” in June 2006. In fact, it was delivered in February 2005, according to the Government Accountability Office, the federal watchdog agency charged with reviewing the study.

%d bloggers like this: